The Usefulness of Tacrolimus Without Basiliximab in Well Matched Living Renal Transplantation in Korea
试验速览
- 阶段
- 不适用
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Incidence of rejection
研究概览
简要总结
Basiliximab has been a routine induction therapeutic agent even for well-matched living kidney transplantation(KT) with tacrolimus-based immunosuppression in Korea. As tacrolimus is a different drug from cyclosporine, the investigators study the usefulness of tacrolimus-based immunosuppression without basiliximab in well matched living KT.
详细描述
The investigators omit basiliximab induction therapy in patients who underwent one to three-HLA mismatched living donor renal transplantation. Participants should receive ABO compatible and T-flow negative transplants. The investigators compare the results of intervention group with conventionally treated control group (age and sex matched patient who underwent one to three-HLA mismatched living donor renal transplants with basiliximab induction therapy).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •ABO compatible and T-flow negative transplants
- •Living kidney transplantation
- •Tacrolimus based immunosuppression
排除标准
- •Multiorgan transplantation
- •Zero-mismatch transplantation (we use cyclosporine instead of FK506)
研究组 & 干预措施
No basiliximab group
The investigators omit basiliximab induction therapy in one to three-HLA mismatched living donor renal transplants.
干预措施: No basiliximab (Drug)
No basiliximab group
The investigators omit basiliximab induction therapy in one to three-HLA mismatched living donor renal transplants.
干预措施: Kidney transplantation (Procedure)
Basilixiab group
Age and sex matched patients who underwent one to three-HLA mismatched living donor renal transplants with basiliximab induction therapy (Control group)
干预措施: Basiliximab (Drug)
Basilixiab group
Age and sex matched patients who underwent one to three-HLA mismatched living donor renal transplants with basiliximab induction therapy (Control group)
干预措施: Kidney transplantation (Procedure)
结局指标
主要结局
Incidence of rejection
时间窗: within 3 years
The investigators measures incidence of rejection by serum creatinine, urinalysis and kidney allograft biopsy.
次要结局
- Incidence of infection(postoperative 6 month, 1 year, 1.5 year, 2 years and 3 years)
研究者
Su-Kil Park
Professor
Asan Medical Center